InsiderTradr

Theralase Technologies Inc. (TLT.V)

TSXV · CAD · Healthcare · Medical Devices

CA$0.20 (-4.76%) as of

Key statistics

Market cap
62.10M
Forward P/E
-20.00
EPS (TTM)
-0.0100
Dividend yield
0.00%
52-week range
0.1500 – 0.4100
Beta
0.41
Revenue (TTM)
802.46k
Profit margin
0.00%
Analyst target
CA$0.70
Volume
27.86k

About Theralase Technologies Inc.

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.

Sector
Healthcare
Industry
Medical Devices
Headquarters
Toronto, ON, Canada

theralase.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks